# Dose Escalation Trial of Neoadjuvant Sorafenib and Concurrent Sorafenib, Cisplatin and Radiation in Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)

> **NCT00627835** · PHASE1 · WITHDRAWN · sponsor: **British Columbia Cancer Agency**

## Conditions studied

- Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)

## Interventions

- **DRUG:** sorafenib
- **DRUG:** sorafenib
- **DRUG:** sorafenib and cisplatin
- **DRUG:** sorafenib and cisplatin
- **DRUG:** sorafenib and cisplatin

## Key facts

- **NCT ID:** NCT00627835
- **Lead sponsor:** British Columbia Cancer Agency
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Site decided not to open this study
- **Last updated:** 2016-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00627835

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00627835, "Dose Escalation Trial of Neoadjuvant Sorafenib and Concurrent Sorafenib, Cisplatin and Radiation in Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00627835. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*